Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab

Luisa Guidi, Alfredo Papa, Antonio Gasbarrini, Alessandro Armuzzi, Gianluca Andrisani, Manuela Marzo, Leonardo Celleno

Risultato della ricerca: Contributo in rivistaArticolo in rivista

34 Citazioni (Scopus)

Abstract

Anti tumor necrosis factor antibodies are used to treat both psoriasis and inflammatory bowel disease. Several paradoxical cases of psoriatic skin lesions induced by tumor necrosis factor antagonist therapy have been described in IBD patients in the recent years. Ustekinumab, a fully human anti-interleukin-12/-23 monoclonal antibody, is the first drug of a new class of biologic therapy approved for the treatment of moderate to severe plaque psoriasis. Data on the efficacy of ustekinumab in patients with moderate-to-severe Crohn's disease, especially in patients previously treated with infliximab, have been recently published. We report about the effectiveness of ustekinumab in the treatment of both severe scalp psoriasis lesions with alopecia and active Crohn's disease.
Lingua originaleEnglish
pagine (da-a)2831-2836
Numero di pagine6
RivistaEuropean Review for Medical and Pharmacological Sciences
Volume17
Stato di pubblicazionePubblicato - 2013

Keywords

  • Crohn's disease
  • infliximab
  • psoriasis

Fingerprint Entra nei temi di ricerca di 'Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab'. Insieme formano una fingerprint unica.

Cita questo